Amicus Therapeutics Inc [NASDAQ: FOLD] closed the trading session at $10.65.
The stocks have a year to date performance of -24.95 percent and weekly performance of 1.53 percent. The stock has been moved at -17.06 percent over the last six months. The stock has performed 6.08 percent around the most recent 30 days and changed 0.95 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 2.47M shares, FOLD reached to a volume of 3250655 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $17.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 30, 2024. The new note on the price target was released on May 14, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise from $15 to $20, while Morgan Stanley kept a Overweight rating on FOLD stock.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.32, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 7.45. The Price to Book ratio for the last quarter was 24.13, with the Price to Cash per share for the same quarter was set at 0.81.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc [FOLD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.53. With this latest performance, FOLD shares gained by 6.08% in over the last four-week period, additionally sinking by -17.06% over the last 6 months – not to mention a drop of -20.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 60.15, with the RSI for the last a single of trading hit 63.60, and the three-weeks RSI is set at 56.71 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 9.99, while it was recorded at 10.63 for the last single week of trading, and 11.38 for the last 200 days.
Amicus Therapeutics Inc [FOLD]: An insightful look at the core fundamentals
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.61 and a Current Ratio set at 3.03.
Amicus Therapeutics Inc [FOLD]: Institutional Ownership
The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in FOLD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in FOLD stock with ownership which is approximately 5.1238%.
